XML 108 R46.htm IDEA: XBRL DOCUMENT
v3.22.0.1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 13 Months Ended | 49 Months Ended | 56 Months Ended
--- | --- | --- | --- | --- | --- | ---
Sep. 30, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2017 USD ($) | May 31, 2017 USD ($) | Dec. 31, 2019 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2021 USD ($) royaltyFee product | Dec. 31, 2020 USD ($) $ / shares | Dec. 31, 2019 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2021 USD ($) milestone | Dec. 31, 2021 USD ($) milestone
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  | $ 110,701,000 | $ 118,192,000 | $ 102,428,000 |  |  |
Pfizer SB-525 |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues under agreement |  |  |  |  |  |  | 55,000,000 |  |  |  |  |
Collaborative arrangement transaction price |  |  |  |  |  |  | 134,000,000 |  |  |  |  |
Research service fees |  |  |  |  |  |  | 79,000,000 |  |  |  |  |
Revenues |  |  |  |  |  |  | $ 0 |  |  |  |  |
Pfizer SB-525 | S B Five Two Five And Other Products |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement, number of milestones achieved | milestone |  |  |  |  |  |  |  |  |  |  |  | 2
Milestone payments received |  |  |  |  |  |  |  |  |  |  |  | $ 55,000,000
Number of products approved | product |  |  |  |  |  |  | 0 |  |  |  |  |
Number of milestones included in transaction price | royaltyFee |  |  |  |  |  |  | 0 |  |  |  |  |
Pfizer, Giroctocogene Fitelparvovec |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues under agreement |  | $ 25,000,000 |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  | $ 0 | 34,449,000 | 39,359,000 |  |  |
Collaborative arrangement, increase (decrease) in revenue |  |  |  |  |  |  |  | (2,400,000) |  |  |  |
Collaborative arrangement, increase (decrease) in net income (loss) |  |  |  |  |  |  |  | $ 2,400,000 |  |  |  |
Collaborative arrangement, net income (loss) per share | $ / shares |  |  |  |  |  |  |  | $ 0.02 |  |  |  |
Pfizer, Giroctocogene Fitelparvovec | Phase Three Clinical Trial |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received | $ 30,000,000 |  |  |  |  |  |  |  |  |  |  |
Cumulative compensation earned |  |  |  |  |  |  |  | $ 30,000,000 |  | $ 30,000,000 |  |
Pfizer, Giroctocogene Fitelparvovec | Amended collaboration and license agreement |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Recognition of milestone |  |  |  |  |  |  |  | 1,300,000 |  | $ 25,000,000 |  |
Pfizer, Giroctocogene Fitelparvovec | Recognition of license and stand-ready fee |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | $ 8,700,000 |  | 0 | 3,111,000 | 15,697,000 |  |  |
Reduction in revenues |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |
Pfizer, Giroctocogene Fitelparvovec | Milestone achievement |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  | $ 0 | 31,338,000 | 23,662,000 |  |  |
Pfizer Inc. |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination, term |  |  |  |  |  |  | 15 years |  |  |  |  |
Collaborative arrangement, increase (decrease) in revenue |  |  |  |  |  |  |  | (8,800,000) |  |  |  |
Collaborative arrangement, increase (decrease) in net income (loss) |  |  |  |  |  |  |  | $ 8,800,000 |  |  |  |
Collaborative arrangement, net income (loss) per share | $ / shares |  |  |  |  |  |  |  | $ (0.06) |  |  |  |
Pfizer Inc. | S B Five Two Five And Other Products |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues under agreement |  |  |  | $ 70,000,000 |  |  |  |  |  |  |  |
Potential amount to be funded for achievement of specified commercialized and sales milestones |  |  |  | 266,500,000 |  |  |  |  |  |  |  |
Milestone revenue receivable |  |  |  | 300,000,000 |  |  |  |  |  |  |  |
Pfizer Inc. | S B Five Two Five And Other Products | Achievement of specified clinical development intellectual property and regulatory milestones |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  |  | 208,500,000 |  |  |  |  |  |  |  |
Pfizer Inc. | S B Five Two Five And Other Products | Achievement of first commercial sale milestones |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  |  | 475,000,000 |  |  |  |  |  |  |  |
Pfizer Inc. | C9ORF72 |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues under agreement |  |  | $ 5,000,000 |  |  |  |  | $ 5,000,000 |  |  |  |
Development and sales-based milestone payments to be received | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement transaction price |  |  | 17,000,000 |  |  |  |  |  |  |  |  |
Pfizer Inc. | Other products |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Milestone revenue receivable |  |  |  | $ 175,000,000 |  |  |  |  |  |  |  |
Pfizer C9ORF72 |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination, term |  |  |  |  |  |  | 15 years |  |  |  |  |
Milestone payments received |  |  | 12,000,000 |  |  |  |  |  |  |  | $ 5,000,000 |
Number of products approved | milestone |  |  |  |  |  |  |  |  |  |  | 0 |
Number of milestones included in transaction price | milestone |  |  |  |  |  |  |  |  |  |  | 0 |
Revenues |  |  |  |  |  |  | $ 0 | 12,985,000 | 1,827,000 |  |  |
Pfizer C9ORF72 | Recognition of license and stand-ready fee |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  | 0 | 7,985,000 | 1,827,000 |  |  |
Pfizer C9ORF72 | Milestone achievement |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  | $ 0 | $ 5,000,000 | $ 0 |  |  |
Pfizer C9ORF72 | C9ORF72 |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenues under agreement |  |  | 12,000,000 |  |  |  |  |  |  |  |  |
Pfizer C9ORF72 | C9ORF72 | Achievement of specified preclinical development clinical development and first commercial sale milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  | 60,000,000 |  |  |  |  |  |  |  |  |
Pfizer C9ORF72 | C9ORF72 | Achievement of commercial milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Development and sales-based milestone payments to be received |  |  | $ 90,000,000 |  |  |  |  |  |  |  |  |

X
- Definition Aggregate additional revenue recognition milestone method revenue eligible to receive. + References No definition available. + Details
Name: | sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Agreement Termination, Term + References No definition available. + Details
Name: | sgmo_AgreementTerminationTerm
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration and license agreements number of products approved under agreement. + References No definition available. + Details
Name: | sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Increase (Decrease) In Net Income (Loss) + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Increase (Decrease) In Revenue + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Net Income (Loss) Per Share + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementNetIncomeLossPerShare
Namespace Prefix: | sgmo_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Number Of Milestones Achieved + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementNumberOfMilestonesAchieved
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Research Service Fees + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementResearchServiceFees
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative arrangement transaction price. + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementTransactionPrice
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Customer contract liability milestone payment eligible to receive. + References No definition available. + Details
Name: | sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments received. + References No definition available. + Details
Name: | sgmo_MilestonePaymentsReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone​ revenue receivable. + References No definition available. + Details
Name: | sgmo_MilestoneRevenueReceivable
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of clinical or regulatory milestones included in transaction price. + References No definition available. + Details
Name: | sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned + References No definition available. + Details
Name: | sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PhaseThreeClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sgmo_AmendedCollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |